Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
Muscle Invasive Bladder Cancer
DRUG: Durvalumab|DRUG: Cisplatin|DRUG: Gemcitabine
Pathologic complete response (pCR) rates at time of cystectomy, Up to 6 months|Event-free survival (EFS) per central review defined as time from randomization to event, Up to 48 months
Proportion of patients who achieve <P2 at time of cystectomy, Up to 6 months|EFS at 24 months (EFS24) defined as time from randomization to event, Up to 24 months|Proportion of patients who undergo cystectomy, Up to 6 months|Overall survival rate at 5 years, Up to 60 months|PFS2 defined as time from randomization to event following subsequent therapy, Up to 84 months|Safety and Tolerability as evaluated by adverse events occurring throughout the study, Up to 84 months|Immunogenicity of durvalumab when used in combination with gemcitabine/cisplatin as measured by presence of antidrug antibodies (ADA), Up to 12 months|Overall Survival, Up to 84 months|Metastasis-free survival per investigator assessment or local biopsy review., Up to 48 months|Disease-specific survival per investigator assessment or local biopsy review., up to 48 months|Disease-free survival, Up to 48 months
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer